Scholarlink

Background <p>The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-free survival (PFS) versus sorafenib. Real-world data are required to further evaluate effectiveness and safety.</p> Methods <p>We conducted a retrospective multicentre analysis across three oncology centres in the Midlands, UK, with audit committee approval. Eligible patients had HCC confirmed histologically where feasible.</p> Results <p>As of August 2025, 233 patients were included, with a median follow-up of 17.4 months (95% CI: 12.6–23.2). Median OS was 16.5 months (95% CI: 14.2–20.7), with 6-month OS of 76.8%. Median PFS was 12.3 months (95% CI: 10.0–16.3), with 6-month PFS of 70.8%. The objective response rate was 42.9%. Treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%). Second-line therapy was administered to 39.1%. Any-grade adverse events occurred in 41.2%, with ≥grade 3 toxicity in 23.2%.</p> Conclusions <p>In this UK real-world cohort, ATE/BEV demonstrated survival outcomes comparable to IMBrave150, with manageable toxicity and meaningful access to subsequent therapy, supporting its effectiveness beyond clinical trial settings.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Richard Phillips,
  • Harry Daniels,
  • Marie Quinlan,
  • Ali Suwaidan,
  • Kaushal Maru,
  • Jake Hancock,
  • Mabel Teng,
  • Jasvinder Kaur,
  • Yuk Ting Ma,
  • Sean Dulloo,
  • Sadaqat Hussain,
  • Basma Greef,
  • Shivan Sivakumar

摘要

Background

The IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-free survival (PFS) versus sorafenib. Real-world data are required to further evaluate effectiveness and safety.

Methods

We conducted a retrospective multicentre analysis across three oncology centres in the Midlands, UK, with audit committee approval. Eligible patients had HCC confirmed histologically where feasible.

Results

As of August 2025, 233 patients were included, with a median follow-up of 17.4 months (95% CI: 12.6–23.2). Median OS was 16.5 months (95% CI: 14.2–20.7), with 6-month OS of 76.8%. Median PFS was 12.3 months (95% CI: 10.0–16.3), with 6-month PFS of 70.8%. The objective response rate was 42.9%. Treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%). Second-line therapy was administered to 39.1%. Any-grade adverse events occurred in 41.2%, with ≥grade 3 toxicity in 23.2%.

Conclusions

In this UK real-world cohort, ATE/BEV demonstrated survival outcomes comparable to IMBrave150, with manageable toxicity and meaningful access to subsequent therapy, supporting its effectiveness beyond clinical trial settings.

Graphical Abstract